Free Trial

Regencell Bioscience (RGC) Competitors

Regencell Bioscience logo
$15.05 -0.13 (-0.86%)
As of 07/25/2025 04:00 PM Eastern

RGC vs. BNTX, SMMT, INSM, TEVA, GMAB, MRNA, RDY, QGEN, VTRS, and ASND

Should you be buying Regencell Bioscience stock or one of its competitors? The main competitors of Regencell Bioscience include BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

Regencell Bioscience vs. Its Competitors

Regencell Bioscience (NASDAQ:RGC) and BioNTech (NASDAQ:BNTX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Regencell Bioscience has a net margin of 0.00% compared to BioNTech's net margin of -27.37%. Regencell Bioscience's return on equity of 0.00% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
BioNTech -27.37%-3.94%-3.41%

In the previous week, BioNTech had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for BioNTech and 3 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.19 beat BioNTech's score of 0.51 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Regencell Bioscience has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Regencell Bioscience has higher earnings, but lower revenue than BioNTech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$4.30MN/AN/A
BioNTech$2.75B10.09-$719.92M-$3.40-33.91

Regencell Bioscience pays an annual dividend of $0.88 per share and has a dividend yield of 5.8%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.3%. BioNTech pays out -45.0% of its earnings in the form of a dividend.

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a consensus price target of $136.58, indicating a potential upside of 18.45%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

BioNTech beats Regencell Bioscience on 9 of the 16 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGC vs. The Competition

MetricRegencell BioscienceMedicinal Chemicals IndustryManufacturing SectorNASDAQ Exchange
Market Cap$7.51B$7.51B$2.27B$9.50B
Dividend YieldN/AN/A2.57%4.00%
P/E RatioN/AN/A22.0720.08
Price / SalesN/AN/A80.1989.31
Price / CashN/AN/A29.1858.56
Price / Book752.50752.5055.705.88
Net Income-$4.30M-$4.30M-$121.61M$258.89M
7 Day Performance3.79%3.79%0.95%3.71%
1 Month Performance-25.46%-25.46%2.11%11.72%
1 Year PerformanceN/AN/A25.27%18.01%

Regencell Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGC
Regencell Bioscience
0.2407 of 5 stars
$15.05
-0.9%
N/AN/A$7.51BN/A0.0010Positive News
BNTX
BioNTech
1.428 of 5 stars
$114.38
+2.6%
$136.58
+19.4%
+36.2%$27.53B$2.75B-33.686,772News Coverage
SMMT
Summit Therapeutics
2.5068 of 5 stars
$27.74
+4.5%
$34.67
+25.0%
+173.3%$20.61B$700K-81.63110Positive News
INSM
Insmed
3.927 of 5 stars
$102.14
-0.8%
$109.20
+6.9%
+39.5%$19.44B$363.71M-17.221,271News Coverage
Analyst Forecast
Insider Trade
TEVA
Teva Pharmaceutical Industries
4.0149 of 5 stars
$16.59
+1.8%
$24.71
+49.0%
-1.6%$19.11B$16.54B-14.4936,830Upcoming Earnings
Analyst Upgrade
GMAB
Genmab A/S
4.0859 of 5 stars
$22.87
+4.9%
$37.80
+65.3%
-16.8%$14.68B$3.12B13.002,682Gap Up
MRNA
Moderna
4.3013 of 5 stars
$35.08
+7.2%
$46.11
+31.4%
-71.6%$13.57B$3.14B-4.025,800Upcoming Earnings
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7396 of 5 stars
$14.73
+2.2%
$16.95
+15.1%
-9.3%$12.28B$3.81B22.2827,811Earnings Report
QGEN
Qiagen
3.6745 of 5 stars
$50.34
+1.7%
$49.40
-1.9%
+26.1%$11.20B$1.98B126.335,765Analyst Downgrade
Analyst Revision
VTRS
Viatris
2.4298 of 5 stars
$9.40
+1.7%
$10.40
+10.7%
-20.0%$11.03B$14.33B-2.9632,000
ASND
Ascendis Pharma A/S
3.436 of 5 stars
$168.21
+1.6%
$223.07
+32.6%
+24.6%$10.30B$393.54M-26.821,017Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:RGC) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners